Premium
Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate
Author(s) -
Termuhlen Amanda M.,
Grovas Alfred,
Klopfenstein Kathryn,
Rosselet Robin,
Gross Thomas G.
Publication year - 2006
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2006.00589.x
Subject(s) - thiotepa , medicine , melphalan , renal function , hematopoietic stem cell transplantation , urology , transplantation , hematopoietic stem cell , chemotherapy , surgery , stem cell , oncology , haematopoiesis , cyclophosphamide , biology , genetics
Normalized glomerular filtration rate (nGFR) <60 mL/min/1.73 m 2 often precludes hematopoietic stem cell transplant (HSCT) in pediatric patients. Three patients with nGFR < 60 mL/min/1.73 m 2 enrolled on an institutional phase I trial of HSCT preparative therapy for advanced and recurrent solid tumors with escalating melphalan, ranging from 135 to 180 mg/m 2 , thiotepa (600 mg/m 2 ), and vincristine (2 mg/m 2 ). An additional patient with low nGFR was treated with the same preparative therapy. None of the patients developed acute renal failure, excess toxicities during HSCT or delayed engraftment. These cases demonstrate that it is feasible and safe to perform HSCT in pediatric patients with low nGFR using melphalan‐ and thiotepa‐based preparative therapy.